Avant BrandsFRA:1BU 35 EBITDA Margin % is -20.39% as of Feb. 2026. GuruFocus rates FRA:1BU with a GF Score™ of 35/100 and a GF Value™ of €0.74 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Avant Brands ranks worse than 84.29% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Avant Brands's EBITDA for the
three
months ended in Feb. 2026 was €-1.79 Mil. Avant Brands's Revenue for the
three
months ended in Feb. 2026 was €8.76 Mil. Therefore, Avant Brands's EBITDA margin for the quarter that ended in Feb. 2026 was -20.39%.
Avant Brands (FRA:1BU) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Avant Brands EBITDA Margin % Related Terms
Avant Brands EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Avant Brands's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Avant Brands's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avant Brands EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Avant Brands's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Avant Brands's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avant Brands (FRA:1BU) has a EBITDA Margin % of -20.39% as of Feb. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Avant Brands and its competitors. According to the industry distribution chart, Avant Brands ranks #805 out of 955 companies in the Drug Manufacturers industry, placing it in the top 84.3%.
Is Avant Brands' EBITDA Margin % too high?
Avant Brands' current EBITDA Margin % is -20.39%. Based on the distribution chart, Avant Brands ranks #805 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Avant Brands has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Avant Brands' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Avant Brands ranks #805 out of 955 companies for EBITDA Margin %. This places Avant Brands in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Avant Brands and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avant Brands's current EBITDA Margin % is -20.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avant Brands stock overvalued right now?
Based on GuruFocus' analysis, Avant Brands (FRA:1BU) is currently considered Possible Value Trap. The stock's GF Value™ is €0.74, compared to a current price of €0.33 — trading 54.9% below its estimated fair value. The current EBITDA Margin % is -20.39%. Avant Brands' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Avant Brands (FRA:1BU), the current EBITDA Margin % is -20.39% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avant Brands (FRA:1BU) Overvalued in 2026?
Based on GuruFocus' analysis, Avant Brands stock appears to be undervalued.
The current stock price of €0.33 is trading 54.9% below its estimated GF Value™ of €0.74.
GuruFocus considers Avant Brands to be Possible Value Trap.
Key valuation signals for FRA:1BU:
EBITDA Margin %: -20.39%
GF Value™: €0.74 vs. price of €0.33 (54.9% below fair value)
No single metric tells the full story. See the FRA:1BU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avant Brands Inc operating in the cannabis industry, engages in the cultivation, production, marketing, and sale of cannabis products. Its product portfolio mainly consists of dried cannabis flower and related cannabis products, with the company managing the entire value chain from cultivation and harvesting to processing, packaging, and distribution, generating revenue upon delivery of products to customers. It operates in Canada.
35GF Score
Get the complete analysis for FRA:1BU
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1BU has been successfully added to your 
